## Contents

### REVIEW

<table>
<thead>
<tr>
<th>Page</th>
<th>Title of Article</th>
<th>Authors</th>
</tr>
</thead>
</table>

### ORIGINAL ARTICLE

#### Clinical and Translational Research

<table>
<thead>
<tr>
<th>Page</th>
<th>Title of Article</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3352</td>
<td>Identification of circ_0000375 and circ_0011536 as novel diagnostic biomarkers of colorectal cancer</td>
<td>Yin TF, Du SY, Zhao DY, Sun XZ, Zhou YC, Wang QQ, Zhou GYJ, Yao SK</td>
</tr>
</tbody>
</table>

#### Retrospective Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title of Article</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3369</td>
<td>Echocardiography in the diagnosis of Shone’s complex and analysis of the causes for missed diagnosis and misdiagnosis</td>
<td>Li YD, Meng H, Pang KJ, Li MZ, Xu N, Wang H, Li SJ, Yan J</td>
</tr>
<tr>
<td>3389</td>
<td>Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients</td>
<td>Ke ZR, Chen W, Li MX, Wu S, Jin LT, Wang TJ</td>
</tr>
<tr>
<td>3401</td>
<td>Washed microbiota transplantation reduces serum uric acid levels in patients with hyperuricaemia</td>
<td>Cai JR, Chen XW, He YJ, Wu B, Zhang M, Wu LH</td>
</tr>
</tbody>
</table>

#### Clinical Trials Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title of Article</th>
<th>Authors</th>
</tr>
</thead>
</table>

### META-ANALYSIS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title of Article</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3436</td>
<td>Accuracy of ultrasound elastography for predicting breast cancer response to neoadjuvant chemotherapy: A systematic review and meta-analysis</td>
<td>Chen W, Fang LX, Chen HL, Zheng JH</td>
</tr>
</tbody>
</table>
### Contents

**Thrice Monthly Volume 10 Number 11 April 16, 2022**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3449</td>
<td>Association of chronic obstructive pulmonary disease with mild cognitive impairment and dementia risk: A systematic review and meta-analysis</td>
<td>Zhao LY, Zhou XL</td>
</tr>
<tr>
<td>3472</td>
<td>Difference and similarity between type A interrupted aortic arch and aortic coarctation in adults: Two case reports</td>
<td>Ren SX, Zhang Q, Li PP, Wang XD</td>
</tr>
<tr>
<td>3478</td>
<td>Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report</td>
<td>Huang KK, Han SS, He LY, Yang LL, Liang BY, Zhen QY, Zhu ZB, Zhang CY, Li HY, Lin Y</td>
</tr>
<tr>
<td>3485</td>
<td>Unusual glomus tumor of the lower leg: A case report</td>
<td>Wang HY, Duan P, Chen H, Pan ZY</td>
</tr>
<tr>
<td>3490</td>
<td>Pulmonary <em>Cladosporium</em> infection coexisting with subcutaneous <em>Corynespora cassiicola</em> infection in a patient: A case report</td>
<td>Wang WY, Luo HB, Hu JQ, Hong HH</td>
</tr>
<tr>
<td>3496</td>
<td>Preoperational diagnosis and management of breast ductal carcinoma <em>in situ</em> arising within fibroadenoma: Two case reports</td>
<td>Wu J, Sun KW, Mo QP, Yang ZR, Chen Y, Zhong MC</td>
</tr>
<tr>
<td>3505</td>
<td>Reconstruction of complex chest wall defects: A case report</td>
<td>Huang SC, Chen CY, Qiu P, Yan ZM, Chen WZ, Liang ZZ, Luo KW, Li JW, Zhang YQ, Huang BY</td>
</tr>
<tr>
<td>3511</td>
<td>Young children with multidrug-resistant epilepsy and vagus nerve stimulation responding to perampanel: A case report</td>
<td>Yang H, Yu D</td>
</tr>
<tr>
<td>3541</td>
<td>Severe gastric insufflation and consequent atelectasis caused by gas leakage using AIR-Q laryngeal mask airway: A case report</td>
<td>Zhao Y, Li P, Li DW, Zhao GF, Li XY</td>
</tr>
</tbody>
</table>
### Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3547</td>
<td>Hypereosinophilic syndrome presenting as acute ischemic stroke, myocardial infarction, and arterial involvement: A case report</td>
<td>Sun RR, Chen TZ, Meng M</td>
</tr>
<tr>
<td>3553</td>
<td>Cytochrome P450 family 17 subfamily A member 1 mutation causes severe pseudohermaphroditism: A case report</td>
<td>Gong Y, Qin F, Li WJ, Li Y, He P, Zhou XJ</td>
</tr>
<tr>
<td>3573</td>
<td>Qingchang decoction retention enema may induce clinical and mucosal remission in left-sided ulcerative colitis: A case report</td>
<td>Li PH, Tang Y, Wen HZ</td>
</tr>
<tr>
<td>3587</td>
<td>Ultrasound-guided local ethanol injection for fertility-preserving cervical pregnancy accompanied by fetal heartbeat: Two case reports</td>
<td>Kakinuma T, Kakinuma K, Matsuda Y, Ohwada M, Yanagida K, Kaijima H</td>
</tr>
<tr>
<td>3593</td>
<td>Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report</td>
<td>Wei HP, Mao J, Hu ZL</td>
</tr>
<tr>
<td>3601</td>
<td>Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report</td>
<td>Liang HP, Liu XC, Zhang YL, Liu B</td>
</tr>
<tr>
<td>3609</td>
<td>Papillary thyroid microcarcinoma with contralateral lymphatic skip metastasis and breast cancer: A case report</td>
<td>Ding M, Kong YH, Gu JH, Xie RL, Fei J</td>
</tr>
<tr>
<td>3615</td>
<td>Contrast-enhanced ultrasound manifestations of synchronous combined hepatocellular-cholangiocarcinoma and hepatocellular carcinoma: A case report</td>
<td>Gao L, Huang JY, Lu ZJ, Lu Q</td>
</tr>
<tr>
<td>3624</td>
<td>Thyrotoxicosis after a massive levothyroxine ingestion: A case report</td>
<td>Du F, Liu SW, Yang H, Duan RX, Ren WX</td>
</tr>
<tr>
<td>3630</td>
<td>Pleomorphic adenoma of the left lacrimal gland recurred and transformed into myoepithelial carcinoma after multiple operations: A case report</td>
<td>Huang WP, Li LM, Gao JB</td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of World Journal of Clinical Cases, Chi-Yuan Yeh, MD, PhD, Assistant Professor, Chief Doctor, radiation oncology, Tungs’ Taichung MetroHarbor Hospital, Taichung 43503, Taiwan. peteryeh46@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC’s CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
April 16, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUC
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.ffipublishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Qingchang decoction retention enema may induce clinical and mucosal remission in left-sided ulcerative colitis: A case report

Pei-Han Li, Yu Tang, Hong-Zhu Wen

Specialty type: Gastroenterology and hepatology
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind

Pei-Han Li, Hong-Zhu Wen, Department of Gastroenterology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

Yu Tang, Department of Basic Medicine, Fudan University, Shanghai 200032, China

Corresponding author: Hong-Zhu Wen, MD, Attending Doctor, Department of Gastroenterology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 725 South Wanping Road, Shanghai 200032, China. ellawhz@sina.com

Abstract
BACKGROUND
Ulcerative colitis (UC) is a chronic autoimmune disease characterized by relapsing-remitting abdominal pain, diarrhea, mucopurulent discharge and rectal bleeding. To date, the etiology of the disease remains unknown; therefore, medical therapy is not yet available. Left-sided UC is mainly treated with oral and topical mesalazine. However, due to its modest clinical effect, endoscopic mucosal remission is not achieved in all patients.

CASE SUMMARY
A 44-year-old man presented to Longhua Hospital with a history of left-sided UC for more than 6 years and slight bloody diarrhea over time. Endoscopy suggested hyperemia, edema, and erosive mucosa involving the rectum and sigmoid colon. The Traditional Chinese medicine Qingchang decoction (QCD) enema treatment was initiated once a day combined with a previous standard dose of mesalazine for 8 wk, and rectal bleeding ceased after 4 wk of treatment. Another QCD enema treatment was provided after symptom relapse due to drug withdrawal for nearly 6 mo. At the 2-mo follow-up, the colonoscopy results indicated mucosal healing with no erosion or ulcers.

CONCLUSION
The Chinese formula QCD retention enema represents a potential treatment for left-sided UC with predominant rectal bleeding to achieve clinical and mucosal remission.

Key Words: Ulcerative colitis; Chinese formulas; Qingchang decoction enema; Qingchang suppository; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: We present a case of a 44-year-old man with mildly active left-sided ulcerative colitis (UC) for 6 years in whom mesalazine treatment failed but clinical and mucosal remission was achieved following Chinese formula Qingchang decoction (QCD) retention enema treatment combined with oral mesalazine. Thus, a QCD enema may be an effective treatment modality for patients with left-sided UC.

Citation: Li PH, Tang Y, Wen HZ. Qingchang decoction retention enema may induce clinical and mucosal remission in left-sided ulcerative colitis: A case report. World J Clin Cases 2022; 10(11): 3573-3578
DOI: https://dx.doi.org/10.12998/wjcc.v10.i11.3573

INTRODUCTION
Ulcerative colitis (UC) is a chronic autoimmune disease characterized by relapsing-remitting abdominal pain, diarrhea, mucopurulent discharge, and rectal bleeding. Its lesions mainly involve the mucous membrane and submucosa of the colon. UC can be divided into proctitis, rectal-sigmoid colitis and extensive colitis[1], corresponding to 14.8%, 26.4% and 25.0% of all UC cases, respectively[2]. Left-sided colitis refers to colitis involving the lower part of the descending colon. The proportion of left-sided colitis in China exceeds 50%. The precise pathogenesis of UC remains unknown; therefore, medical therapy to cure the disease is not yet available. Therapeutic drugs include sulfasalazine, mesalazine, corticosteroids, immunosuppressants, and biological agents[3]. However, not all patients benefit from basic mesalazine and amino-salicylic acid treatment for left-sided UC. We report herein a case of a 44-year-old man with left-sided UC in whom standard oral and topical doses of mesalazine failed but clinical remission and mucosal healing were eventually achieved with the Chinese formula Qingchang decoction (QCD) enema. This publication reports and discusses the effects of QCD enema treatment on left-sided UC.

CASE PRESENTATION
Chief complaints
A 44-year-old Chinese man presented to Longhua Hospital with a history of left-sided UC for more than 6 years. He received oral treatment with mesalazine at a dose of 3 g/d (occasionally 2 g/d due to forgetting to take the medicine). Bowel movements were maintained 2-3 times a day, with a small amount of blood and mucus in the stool less than half of the time. Mesalazine suppository therapy and glucocorticoid enema were also administered briefly during this period, but the symptoms were not relieved. In the previous 6 years, colonoscopy was repeated annually, with results revealing a Mayo endoscopic score of 2 (erosion of the rectum and sigmoid colon covered with purulent secretions).

History of present illness
The patient suffered from recurrent bloody mucous stool. After another colonoscopy was conducted at a local hospital on October 30, 2019 (Figure 1), which suggested a diagnosis of active left-sided UC, he was admitted to our department on November 09, 2019. He reported bowel movements twice a day; mild, dull pain in the left lower abdomen that was relieved after a bowel movement; relapsing mucous discharge; and rectal bleeding when he was fatigued. We observed his tongue to be red with light yellow fur and a thin pulse.

History of past illness
The patient had no significant previous medical history.

Personal and family history
The patient had no significant family history.

Physical examination
Physical examination showed no obvious abnormalities, except for slight tenderness in the left lower abdomen.

Laboratory examinations
No sign of inflammation was found in the blood analysis, and the leukocyte level was low, at 3.55 × 10⁹ /L, with predominant neutrophils (67.1%) and normal hemoglobin and platelet counts. The
prothrombin level, partial thromboplastin times, and d-dimer levels were normal. The serum C-reactive protein level was also within normal limits, and the erythrocyte sedimentation rate was 2 mm/h. The blood biochemistry and urine analyses were normal. The ECG results were also normal.

**Imaging examinations**

Mild inflammation, characterized by hyperemia, edema, erosions and friability was detected in the sigmoid colon (Figure 1A) and rectum (Figure 1B), 20 cm from the anus. Normal mucosa was noted in the remaining colon.

**FINAL DIAGNOSIS**

The patient was diagnosed with UC subtyped as left-sided colitis based on endoscopy of the rectum and colon (Figure 1) and histology of the biopsy. His condition was mild in severity with an active persistent phase. The relevant Traditional Chinese medicine (TCM) syndrome was spleen deficiency and the accumulation of dampness and heat.

**TREATMENT**

Treatment with QCD enema was administered to the patient at a dose of 180 mL once a night, combined with oral mesalazine at a dose of 3 g/d. Rectal bleeding ceased after 4 wk of treatment, and after 8 wk of treatment, the patient had one or two bowel movements per day, and no mucous or bloody discharge was observed. Due to the satisfactory effect, the dose of oral mesalazine was reduced to 2 g/d, and enema therapy was stopped without a consultation. On June 22, 2020, the patient came to our ward for further treatment with QCD enema. The stool frequency was reduced to 2 to 3 times a day, with no mucus or blood present after 4 wk of treatment.

**OUTCOME AND FOLLOW-UP**

The patient received a total of 12 wk of QCD retention enema treatment combined with oral mesalazine. After the second episode of QCD treatment, on August 07, 2020, a colonoscopy was performed again. Normal mucosa was seen in the sigmoid colon (Figure 2A), and relative healing with patchy hyperemia was detected in the rectum (Figure 2B). The endoscopic Mayo score was evaluated as 1, which indicated that the integrated treatment induced both clinical and endoscopic remission. Subsequently, oral mesalazine was continued at a dose of 2 g/d with a QCD retention enema twice a week. The patient was last followed up on September 28, 2021, and he had no abdominal pain, nor bloody stool with mucus.
DISCUSSION

As a subtype of inflammatory bowel disease (IBD), UC is characterized by chronic inflammation of the colonic mucosa and recurrent attack. The exact etiology and pathogenesis of UC remain unclear, and treatment options are limited. For long-standing UC, typically 8 or 10 years after disease onset, there is a defined risk of dysplasia and colorectal cancer caused by persistent large-scale colonic inflammation\[^4\].

A targeted therapy that focuses on endoscopic mucosal healing rather than mere symptom remission has emerged as a new preferred concept in the management approach of IBD\[^5\]. Mucosal healing refers to the resolution of inflammatory changes (Mayo endoscopic subscore of 0 or 1)\[^5\]. It is essential to manage UC in the remission phase with the minimum category or dose of medicine due to the limited choice of medications.

The guidelines recommend oral mesalazine at a dose of ≥ 2.4 g/d combined with an amino-salicylic acid preparation enema ≥ 1 g/d as a first-line treatment for mild to moderate left-sided UC\[^3\]. The guidelines also indicate that the local effect of mesalazine is better than that of topical corticosteroids. However, not all patients benefit from this treatment. For instance, the study by Marteau \textit{et al}\[^6\] showed that the remission rate of UC treated with mesalazine at a dose of 4 g/d combined with 1 g/d enema was 64%. A randomized controlled trial (RCT) by Hartmann \textit{et al}\[^7\] used mesalazine or budesonide enema therapy for patients with mild to moderate left-sided UC. The proportion of these patients in whom endoscopic remission (defined as an endoscopic score < 2) was achieved was 71.7% (76/106) and 68.0% (76/103), respectively. Bokemeyer \textit{et al}\[^8\] reported that 78.8%-84.4% of left-sided UC patients were assigned an endoscopic score of 0 or 1 (0 = normal or inactive disease; 1 = mild disease, erythema, decreased vascular pattern, and mild friability) after 12 mo of oral mesalazine at a dose of 2 g/d. In conclusion, oral mesalazine and/or enema therapy is ineffective for approximately 20% to 30% of patients with left-sided UC. The guidelines\[^5\] recommend using systemic corticosteroid therapy, but a large portion of patients in practice are unwilling to receive oral or intravenous corticosteroid therapy due to their side effects. For patients with poor outcomes with mesalazine treatment and who are unwilling to accept systemic corticosteroid treatment, TCM therapy is an effective option, which is also documented in China’s IBD guidelines\[^1\].

Although UC has no corresponding disease name in TCM, it has long been recorded throughout history and is well understood. According to the description of the clinical manifestations of “changpi”, “Xiali”, “chronic dysentery”, and “recurrent dysentery” in the medical documents of the previous dynasties, it is not difficult to connect these diseases with UC. According to TCM theory, UC is located in the large intestine, and the main pathogenesis lies in dampness and heat accumulation. The stagnation of qi and blood with dampness and heat thus leads to the formation of pus. Heat toxicity also burns intestinal collaterals, causing blood perfusion outside of the collaterals. These pathological processes induce symptoms such as abdominal pain, diarrhea, and mucopurulent bloody stools. In the mid-1980s, Gui-Tong Ma, a renowned doctor at Longhua Hospital, developed the Qingchang suppository (QCS), which was the first suppository for rectal administration composed of pure Chinese herbs in China. QCS exerts its effect of clearing heat and dampness, promoting blood circulation and removing blood stasis by targeting four major pathogenic factors, namely, dampness, heat, toxicity, and blood stasis.

The QCS (Z05170722) consists of \textit{Indigo naturalis} (IN), \textit{Radix notoginseng}, \textit{Gallnut}, \textit{Herba portulacae} and \textit{Borneol}\[^9\]. As the most essential component of QCS, IN is a commonly used Chinese herb to cure UC by
reducing inflammation and rectal bleeding. A randomized, placebo-controlled trial conducted by Japanese researchers demonstrated that 8 wk of IN administration (0.5-2.0 g per day) induced a clinical response and mucosal healing in patients with active UC[10]. IN includes indigo and indirubin molecules[11], which act as representative human aryl hydrocarbon receptor (AHR) ligands. AHR signaling stimulates the production of interleukin-22 in mucosal type 3 innate lymphocytes, thus inducing the production of tight junction molecules and antimicrobial peptides, which contribute to mucosal healing[12]. IN also has an anti-inflammatory role by downregulating proinflammatory factors such as IL-1α, IL-6, IL-1β, IL-8 and TNF-α[13].

The mechanism of QCS has also been fully investigated. Sun et al[9] used QCS and sulfasalazine suppository (SASP) to treat rats with dextran sulfate sodium-induced colitis and normal control rats. The levels of the proinflammatory factors TNF-α and IL-6 were suppressed with both treatments, suggesting that QCS has anti-inflammatory effects. Moreover, the production of vascular endothelial growth factor (VEGF), hypoxia-inducible factor (HIF)-1α, and inducible NO synthase (iNOS) was also inhibited in the QCS- and SASP-treated groups, suggesting that QCS can restrain colonic vascular permeability and promote epithelial integrity and colonic hypoxia. Lu et al[14] administered low, medium, and high doses of QCS and SASP to rats with trinitro-benzene-sulfonic acid (TNBS)-induced colitis and observed the expression of F-actin protein, which is a major component of the cytoskeleton, through immunofluorescence. The study revealed that QCS can improve F-actin protein content based on reduction after modeling, which suggested that it can reduce the damage of UC to the mucosal cytoskeleton and protect the integrity of the intestinal barrier. These studies support the notion that QCS can effectively alleviate colonic inflammation in UC.

The clinical effect of QCS has been fully investigated. However, clinical trials aiming to identify the effect of QCD enema have not yet been conducted. A previous multicenter RCT demonstrated that an efficacy rate of 91.49% after 8 wks after the initiation of QCS treatment at a dose of 2 g/d was achieved in patients with mild to moderate proctitis compared with 87.23% in the SASP treatment group (P > 0.05) [15]. Complete efficacy was defined as the basic disappearance of clinical symptoms and mild mucosal inflammation or the formation of pseudopolyps found by colonoscopy. The outcome of this study also demonstrated that QCS has more advantages in relieving symptoms such as abdominal pain and distention, tenesmus, mucopurulent stool, and burning anal pain. After a one-year follow-up of the QCS group (9.3%), the recurrence rate was significantly lower than that of the SASP group (26.83%). These results indicated that QCS is effective in inducing and maintaining clinical and mucosal remission.

Considering that the suppository application location is mainly limited to the rectum while an enema can reach the descending colon, a QCD enema was thus developed according to the components of QCS for the treatment of left-sided UC. In the case reported here, the patient with active left-sided UC suffered for 6 years after standard oral therapy with mesalazine and intermittent topical treatment. Based on oral mesalazine maintenance treatment, an additional QCD enema at a dose of 180 mL/d successfully induced endoscopic mucosal healing. Although this is a case report, it provides preliminary evidence for the treatment of active left-sided UC. In the future, we will continue to follow up with this patient and collect more cases of QCD treatment for UC to provide more evidence for its treatment effect in left-sided UC.

CONCLUSION

The case described herein demonstrates that the Chinese formula QCD retention enema can effectively reduce both the clinical and mucosal remission of left-sided UC, thus providing another effective therapy other than mesalazine. This finding provides a new understanding of the treatment of left-sided UC and a basis for further studies to determine the underlying mechanism of the QCD treatment effects.

FOOTNOTES

Author contributions: Li PH interpreted and reviewed the literature; Tang Y contributed to manuscript drafting and revision; Wen HZ was the patient’s attending doctor and was responsible for revising the manuscript for important intellectual content; all authors issued final approval of the version to be submitted.

Supported by National Natural Science Foundation of China, No. 81703986.

Informed consent statement: Informed written consent was obtained from the patients for the publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Chinese medicine enema for UC treatment

REFERENCES


